• 1
    Silverman WA, Chalmers I. Sir Austin Bradford Hill: an appreciation. Control Clin Trials. 1992;13:100-105.
  • 2
    Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276:637-639.
  • 3
    National Comprehensive Cancer Network (NCCN). NCNN Clinical Practice Guidelines in Oncology (version 1.2007). Available at: Ac-cessed March 15, 2008.
  • 4
    American Society of Clinical Oncology. Clinical Practice Guidelines. Available at: Accessed March 20, 2012.
  • 5
    US Senate. Patient Protection and Affordable Care Act 2010. Available at: Accessed September 7, 2012.
  • 6
    US Preventive Services Task Force Grade Definitions. Available at: Accessed September 7, 2012.
  • 7
    UK National Health Service. Oxford Centre for Evidence-based Medicine – Levels of Evidence. Available at Accessed September 7, 2012.
  • 8
    Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-145.
  • 9
    Jadad AR, Rennie D. The randomized controlled trial gets a middle-aged checkup. JAMA. 1998;279:319-320.
  • 10
    Brass EP. The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther. 2010;87:351-355.
  • 11
    Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20:637-648.
  • 12
    Bekelman JE, Shah A, Hahn SM. Implications of comparative effectiveness research for radiation oncology. Practical Radiat Oncol. 2011;1:2-80.
  • 13
    Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624-1632.
  • 14
    Elting LS, Cooksley C, Bekele BN, et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006;106:2452-2458.
  • 15
    Flather M, Delahunty N, Collinson J. Generalizing results of randomized trials to clinical practice: reliability and cautions. Clin Trials. 2006;3:508-512.
  • 16
    National Cancer Institute (NCI). NCI Physician Data Query (PDQ) Guidelines. Available at: Accessed March 15, 2008.
  • 17
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
  • 18
    Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 1996;14:1065-1070.
  • 19
    Feinberg BA, Lang J, Grzegorczyk J, et al. Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers. J Oncol Pract. 2012;8(3 suppl):e38s-e43s.
  • 20
    Arrow K, Auerbach A, Bertko J, et al. Toward a 21st-century health care system: recommendations for health care reform. Ann Intern Med. 2009;150:493-495.
  • 21
    Maclennan SJ, Imamura M, Omar MI, et al. Urological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines. World J Urol. 2011;29:291-301.
  • 22
    Lougheed MD, Olajos-Clow JG. Asthma care pathways in the emergency department. Curr Opin Allergy Clin Immunol. 2010;10:181-187.
  • 23
    Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA. 2000;283:749-755.
  • 24
    Maher J. A piece of my mind. Lack of data. JAMA. 2012;308:1331-1332.
  • 25
    Garber AM. Evidence-based coverage policy. Health Aff (Millwood). 2001;20:62-82.
  • 26
    Antman K, Amato D, Wood W, et al. Selection bias in clinical trials. J Clin Oncol. 1985;3:1142-1147.
  • 27
    Edwards SJ, Lilford RJ, Braunholtz DA, Jackson JC, Hewison J, Thornton J. Ethical issues in the design and conduct of randomised controlled trials. Health Technol Assess. 1998;2:i-vi, 1-132.